Analysis of liquid biopsy samples provides a real-time snapshot of tumour burden.
The distinctive DNA circuitry, in conjunction with the universal, electrochemical sensing platform, provides a promising application for the detection of miR-155 or other disease-related oligonucleotide; this circuitry can be extended further to clinical diagnosis of liquid biopsy samples for patients with mammalian lymphoma.
CTC analysis has the unique potential to offer a minimally invasive 'liquid biopsy' sample, easily obtainable at multiple time points during disease history, thus providing valuable information on the very early assessment of treatment efficacy and helping towards establishing individualised treatment approaches that will improve efficacy with less cost and side effects for BC patients.
The blood was processed through a prototype liquid biopsy cell sample preparation instrument as previously described [ 13].
Taken together, it may well be hypothesised that tumour tissue is not the relevant starting material and the liquid biopsy represented by a blood sample should be the material of choice.
Assays that allow the repetitive monitoring of patients by using blood samples as liquid biopsy may be efficient in assessing cancer progression in patients whose tumor tissue is not available.
First, liquid biopsies allow longitudinal sampling using a routine and minimally invasive procedure (blood sampling).
Finally, we have included new strategies in recent markers of liquid biopsy or updated technologies for minimal samples analysis.
Thus, ExMVs enriched in RNA species became a focus of interest in several biological processes related to tissue and organ regeneration and as a potential diagnostic tool to detect pathological RNA species in the abovementioned liquid biopsies performed on samples aspirated from biological fluids (e.g., from blood plasma, ascites, pleural effusion) [17].
Technical advances in tests and processing samples would help this liquid biopsy to have broad clinical applications, especially in elucidation of resistant mechanisms.
Liquid biopsy extracts cancer cells from a simple blood sample and has the potential to revolutionize cancer treatment by non-invasively monitoring cancer cells.
